Closely-held Ocutrx Vision Technologies reported that its augmented reality (AR) glasses significantly improved functional vision compared with standard near correction glasses, or no correction, in subjects with...
H.C. Wainwright upgraded ReWalk Robotics (NASDAQ:RWLK) to “buy” from “neutral” and raised its price target to $9 from $4, citing several key milestones in the past few months. The stock closed at $5.21 on June 14.
Karyopharm Therapeutics (NASDAQ:KPTI) provided new and updated data from its Phase 1b/2 study evaluating selinexor and dexamethasone in combination with standard approved multiple myeloma (MM) therapies.
Kura Oncology (NASDAQ:KURA) provided updated interim data from its Phase 2 trial of tipifarnib in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Progenics Pharmaceuticals (NASDAQ:PGNX) dosed the first patient in a Phase 2 clinical study evaluating I-131 1095 radiotherapy for the treatment of metastatic castration resistant prostate cancer (mCRPC).
NuCana (NASDAQ:NCNA) received the FDA’s orphan drug designation for acelarin, a nucleoside analog of gemcitabine, for the treatment of biliary tract cancer.
Landenburg Thalmann downgraded Savara (NASDAQ:SVRA) to “neutral” from “buy” and slashed its price target to $3 from $21 after lead asset, Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage...
H.C. Wainwright slashed its price target for Tetraphase Pharmaceuticals (NASDAQ:TTPH) to $1.50 from $7 after the company unveiled a sweeping corporate reorganization. The stock closed at 74 cents on June 12.
Nuvectra (NASDAQ:NVTR) filed a regulatory submission with the FDA for conditional approval of full-body magnetic resonance (MR) imaging in patients implanted with the company’s Algovita spinal cord stimulation (SCS)...